Fig. 1
From: Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Molecular features of HER2+ BC biopsies associated with trastuzumab cytotoxic and cytostatic activity. a Scheme of the number of tumours in each group. C+: responders (patients who experienced a reduction of at least 20% in tumour volume); C−: non-responders. K+: responders (patients who experienced a reduction of at least 50% in the number of Ki67-positive cells in their tumours after treatment with trastuzumab); K−: non-responders. b Averaged normalised enrichment score (NES) of pathways in each cluster significantly enriched (FDR <10%) in each comparison. Clusters were visualised using Cytoscape and labelled manually. Grey squares indicate no significant enrichment. c GSEA enrichment plots of PD1 gene set in C+ compared with C− tumours. NES, normalised enrichment score. d Expression of MHC-II metagene according to tumour partition based on C and K responses. p-value by unpaired t-test
